Abbott Laboratories engages in the discovery, development, manufacture, and sale of a broad and diversified line of health care products. It operates through the following business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Medical Devices segment includes electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care products for people with diabetes, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.

GenVec, Inc. (NASDAQ: GNVC) GenVec, Inc. is a biopharmaceutical company using differentiated, proprietary technologies to create superior therapeutics and vaccines. A key component of our strategy is to develop and commercialize our product candidates through collaborations. GenVec is working with leading companies and organizations such as Novartis, Merial, and the U.S. Government to support a portfolio of product programs that address the prevention and treatment of a number of significant human and animal health concerns. GenVec’s development programs address therapeutic areas such as hearing loss and balance disorders; as well as vaccines against infectious diseases including respiratory syncytial virus (RSV), herpes simplex virus (HSV), dengue fever, influenza, malaria, and human immunodeficiency virus (HIV). In the area of animal health we are developing vaccines against foot-and-mouth disease (FMD).

The Institute Pasteur is a private, non-profit foundation. Its mission is to help prevent and treat diseases, mainly those of infectious origin, through research, teaching, and public health initiatives.The Institut Pasteur is a research center of international renown ideally located in the very heart of Paris. Each year the institute hosts a multitude of scientific and medical conferences and meetings as well as events on a variety of themes.

Syn X Pharma, Inc. develops diagnostic and risk management test. The company was founded by Yahia A. Gawad and George Jackowski and is headquartered in Toronto, Canada.

Bristol-Myers Squibb Company, through its subsidiaries, engages in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of pharmaceuticals and nutritional products. The company operates in two segments, Pharmaceuticals, and Nutritionals. The Nutritionals segment is operated through the company's subsidiary Mead Johnson Nutrition Company (Mead Johnson). The Pharmaceuticals segment is made up of the global pharmaceutical and international consumer medicines business.

Roche Diagnostics GmbH, part of Roche Holding AG, is a company headquartered in Mannheim, Germany, involved in laboratory analytical instruments. Andreas Schmitz and Claus Haberda are the current co-CEOs of the firm. On January 01, 1999 Roche Holding AG acquired Roche Diagnostics GmbH.

NsGene A/S identifies neurotrophic proteins with therapeutic effects in the nervous system. It is a biotechnology company that focuses primarily on neurodegenerative disorders. The firm provides technologies that target protein therapeutics across the blood-brain-barrier and directly to diseased nerve cells. It develops therapeutic products for multiple indications with high medical needs including Alzheimer’s disease, Parkinson's disease, deafness, neuropathic pain, epilepsy, cortico-basal degeneration, and Huntington’s disease. The company was founded by Lars Ulrik Wahlberg and Teit Eliot Johansen in 1999 and is headquartered in Ballerup, Denmark.

Viela Bio, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatment for autoimmune and inflammatory diseases. The firms product candidate includes inebilizumab, which is a humanized monoclonal antibody (mAb), designed to target CD19, a molecule expressed on the surface of a broad range of immune system B cells; VIB4920, which is a fusion protein designed to bind to CD40L on activated T cells, blocking their interaction with CD40-expressing B cells and potentially other binding partners; and VIB7734, which is a humanized mAb intended to be a novel treatment for autoimmune diseases where the pathology is driven principally by overproduction of type I interferons and other cytokines secreted by pDCs. The company was founded on December 11, 2017 and is headquartered in Gaithersburg, MD.

Banyan Biomarkers was founded in 2002 by Ron Hayes, PhD , Kevin Wang, PhD, and Nancy Denslow, PhD to create the first Point of Care (POC) Blood Test to diagnose traumatic brain injury (TBI). Currently no blood test exists for use by physicians to detect the presence and severity of brain trauma. Banyan Biomarkers’ research has identified unique and proprietary biomarkers present in the patient’s blood following injury to the brain. The detection and quantification of these biomarkers may provide early indications of brain trauma essential for earlier intervention and management.

Upfront Diagnostics has discovered and validated novel blood biomarkers for the detection of stroke patients suffering from a large vessel occlusion. Biomarkers enable faster and more accurate stroke diagnosis which will decrease the time to treatment, reducing disabilities and deaths after a stroke. Upfront Diagnostics owns a family of patents which protects novel biomarkers for stroke detection.

The United States Department of Veterans Affairs (VA) is a federal Cabinet-level agency that provides near-comprehensive healthcare services to eligible military veterans at VA medical centers and outpatient clinics located throughout the country; several non-healthcare benefits including disability compensation, vocational rehabilitation, education assistance, home loans, and life insurance; and provides burial and memorial benefits to eligible veterans and family members at 135 national cemeteries.

Nanogen, Inc., a diagnostics company, engages in developing, manufacturing, and selling diagnostic products for use in the in vitro diagnostic market in the United States, Canada, and Europe. It offers diagnostic test kits and reagents based on polymerase chain reaction (PCR) technology in the molecular diagnostic market. The company’s PCR molecular product lines comprise Q-PCR Alert products for in-vitro diagnostic use, and are sold in Italy via a contract sales force and in other European countries through a network of distributors; and MGB Alert products. It also offers point-of-care products, which include qualitative cardiac test products that are rapid test assays used in emergency care settings for the diagnosis of myocardial infarction; quantitative cardiac tests, a quantitative test measuring the concentration of the peptide NT-proBNP for the diagnosis of congestive heart failure; and pandemic influenza test that detects and differentiates the various strains of influenza, including potential pandemic strains. The company was founded in 1993 and is headquartered in San Diego, California. On May 13, 2009, Nanogen, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the US Bankruptcy Court for the District of Delaware.

Shengzhan Biotechnology Co., Ltd. was established in April of the Republic of China. It is an emerging important strategic industry. Its business is based on biotechnology, including microbial fermentation technology, research and development and production of APIs, health food ingredients, animal feed additives. And agricultural biotechnology products. The domestic stock listed company Shengda Chemical Pharmaceutical Co., Ltd. is the parent company of the company holding more than 50% of the shares. The company is a subsidiary of Shengda Company which is vertically integrated, aiming at developing high-tech and high value-added products. Reduce costs and benefit more people.

Bioventures LLC is an American private company located in Tulsa, OK, that develops pharmaceutical products. The firm was founded in 2004.

Shandong Labo Biotechnology Co., Ltd., established on 2005-05-13, The scope of business includes the production of medical devices,Sales;Disinfectant production(Free of Hazardous Chemicals);Disinfectant sales(Free of Hazardous Chemicals);glassware,Office Supplies,Sales of Electronics;Import and export(Except for the import and export of goods and technologies that are prohibited by the state or involve administrative approval);Medical Device Repair,Leasing and technical consulting services.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Zhuhai Hopkins Medical Research Institute Co., Ltd., established on 2012-02-02, The business scope includes the business scope recorded in the articles of association:biomedicine,Research and development of biotechnology products,technology transfer,technical consulting,Technical Services;Chinese herbal medicine,Research and development of western medicine and health food,production and sales;Research and development of beauty products,production and sales;Carry out stem cell collection in units stipulated by the Health and Medical Commission,Production of stem cell preparations,Clinical application of stem cell transplantation technology and production of tissue engineering products;Immune Cell Technology Services;Genetic testing and disease screening services;Related technical services provided by the laboratory;Carry out publicity activities related to medicine,Organization planning consultation and conference services;226/326Physiotherapy and Rehabilitation Equipment,230medicalXX-ray equipment,240Clinical Laboratory Analytical Instruments,255Dental equipment and appliances,264/364Medical hygiene materials and dressings,266Medical polymer materials and products,321Medical electronic equipment,322Medical Optics,Instruments and endoscopic equipment,325Sales of medical high-frequency equipment;.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Gaokang Daily Chemical Group Co., Ltd., established on 2013-07-18, The scope of business includes the manufacture of daily chemical products;Network technology service;Cosmetics Retail;Cosmetics Wholesale;Wholesale of kitchenware, sanitary ware and daily sundries;Wholesale of protective equipment for medical staff;daily mask(non-medical)Sales;Disinfectant sales(Free of Hazardous Chemicals);Sales of hygiene products and single-use medical products;Sales of special labor protection products;Sales of labor protection products;Household Goods Sales;needle textile sales;Wholesale of photographic equipment and binoculars;Lighting Sales;Daily miscellaneous goods sales;Clothing and apparel wholesale;Wholesale shoes and hats;General merchandise sales;Sales of Class II Medical Devices;Sales of industrial textile products;Wholesale medical masks;Metal Products Sales;Office Equipment Sales;Fire Equipment Sales;Domestic trade agent;sales agent;Sales of daily chemical products;Metal Tool Sales;Cosmetic production;Import and export